C-Reactive Protein and Matrix Metalloproteinase-9 are Associated with Outcome of Ischemic Stroke

Yenny Surjawan, Suryani As'ad, Teguh A S Ranakusuma, Andi Wijaya

Abstract


BACKGROUND: C-Reactive protein (CRP) and matrix metalloproteinase (MMP)-9 are inflammatory mediators that are often associated with the evolution of stroke. In this study, we aimed to find out whether concentration of these biomarkers were associated with the severity of discharge National Institute of Health Stroke Scale (NIHSS) in ischemic stroke patient.

METHODS: In prospective stody, we involved 143 ischemic stroke patient who were admitted to hospital not more than 72 hours after the onset and who met the criteria. The concentration of CRP was assessed by High Sensitivity CRP reagent from Siemens and the concentration of MMP-9 was measure with Quantikine Human MMP-9 (total) Immunoassay from R&D. The outcome of stroke was determined by NIHSS score at discharge.

RESULTS: There was a significant correlation between the CRP level and the severity of NIHSS at discharge (r = 0.288, p = 0.000). Subjects with intermediate/high level of CRP had a higher probability to have a moderate or even severe NIHSS (OR = 1.7, p = 0.004). Subjects with high MMP level showed a higher probability to have a severe NIHSS.

CONCLUSION: The measurement of CRP and MMP-9 at 48-72 hours after stroke onset were associated with the severity of ischemic stroke based on NIHSS score at discharge. 

KEYWORDS: inflammation, CRP, MMP-9, discharged NIHSS


Full Text:

PDF

References


Benakis C, Hirt L, Du Pasquier RA. Inflammation and stroke. Kardiovaskulare Medizine. 2009; 12: 143-50, article.

Lakhan EL, Kirchgessner A, Hofer M. Inflammatory mechanisms in ischemic stroke: theraupetic approaches. J Transl Med. 2009; 7: 97-107, CrossRef.

Yeh ET. CRP as a mediator of disease. Circulation. 2004; 109: II-11-14, CrossRef.

Elkind MSV, Tai W, Coates K, Paik MC, Sacco RL. Highsensitive C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med. 2006; 166: 2073-80, CrossRef.

Whiteley W, Wei LC, Sengupta A, Sandercock P. Blood markers for the prognosis of ischemic stroke: a systematic review. Stroke. 2009; 40: e380-9, CrossRef.

Rosenberg GA. Matrix metalloproteinase and proteolytic opening of the blood brain-barrier in neuroinflamation. In: deVries E, Prat A, editors. The blood-brain barrier and its microenvironment basic physiology to neurological disease. New York: Taylor and Francis Group; 2005. p.335-58, NLMID.

Saenger AK, Christenson RH. Stroke biomarkers: progress and challenges for diagnosis, prognosis, differentiation, and treatment. Clin Chem. 2010; 56: 21-33, CrossRef.

Lynch JR, Blessing R, White WD, Grocott HP, Newman MF, Laskowitz DT. Novel diagnostic test for acute stroke. Stroke. 2004; 35: 57-63, CrossRef.

Reynolds MA, Kirchick HJ, Dahlen JR, Anderberg JM, McPherson PH, Nakamura KK, et al. Early biomarkers of stroke. Clin Chem. 2003; 49: 1733-9, CrossRef.

Endres M, Dirnagil U, Moskowitz MA. The ischemic cascade and mediators of ischemic injury. In: Fisher M, editor. Handbook of clinical neurology, vol 92. (3rd series) Stroke. Part I. Boston: Elsevier; 2009. p.31-41, NLMID.

Graham SH, Hickey RW. Molecular pathophysiology of stroke. In: Davis KL, Charney D, Coyle JT, Nemeroff C, editors. Neuropsychopharmacology: the fifth generation of progress. Pennsylvania: American College of Neuropsychopharmacology; 2002. p.1317-26, NLMID.

Jin R, Yang G, Li G. Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J Leukoc Biol. 2010; 87: 779-80, CrossRef.

Garden GA, Moller T. Microglia biology in health and disease. J Neuroimmune Pharmacol. 2006; 1: 127-37, CrossRef.

D’Ambrosio AL, Pinsky DJ, Connolly ES. The role of complement in ischemia/reperfusion injury: implications for neuroprotection. Mol Med. 2001; 7: 367-82, PMID.

Muir KW, Weir CJ, Alwan W, Squire IB, Lees KR. C-reactive protein and outcome after ischemic stroke. Stroke. 1999: 30: 981-5, CrossRef.

Di Napoli M, Papa F, Bocola V. Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke. 2001: 32: 133-8, CrossRef.

Di Nappoli M, Schwaninger M, Capelli R, Ceccarelli E, Gianfilippo GD, Donati C, et al. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP pooling project members. Stroke. 2005; 36: 1316-29, CrossRef.

Kuhlmann CRW, Librizzi L, Closhen D, Pflanzner T, Lessmann V, Pietrzik CU, et al. Mechanisms of C-reactive proteininduced blood-brain barrier disruption. Stroke. 2009; 40: 1458-66, CrossRef.

Mold C, Du Clos TW. C-reactive protein increases cytokine responses to Streptococcus pneumoniae through interactions with Fc{gamma} receptors. J Immunol. 2006; 176: 7598-604, CrossRef.

Zhao BQ, Tejima E, Lo EH. Neurovascular proteases in brain injury, haemorrhage and remodeling after stroke. Stroke. 2007; 38: 748-52, CrossRef.

Serena J, Blanco M, Castellanos M, Silva Y, Vivancos J, Moro MA, et al. The prediction of malignant cerebral infarction by molecular brain barrier disruption markers. Stroke. 2005; 36: 1921-6, CrossRef.




DOI: https://doi.org/10.18585/inabj.v4i3.176

Copyright (c) 2012 The Prodia Education and Research Institute

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

Indexed by:

                  

               

                

 

 

The Prodia Education and Research Institute